Simulations Plus (SLP) to Release Earnings on Thursday

Simulations Plus (NASDAQ:SLP) is anticipated to release its Q2 2026 results after the market closes on Thursday, April 9th. Analysts expect Simulations Plus to post earnings of $0.27 per share and revenue of $21.6590 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 5:00 PM ET.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.05). The company had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same quarter in the previous year, the firm posted $0.17 EPS. On average, analysts expect Simulations Plus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Simulations Plus Trading Up 1.5%

NASDAQ SLP opened at $12.65 on Wednesday. The stock’s 50-day moving average price is $12.76 and its two-hundred day moving average price is $16.02. The company has a market cap of $254.90 million, a PE ratio of -3.95 and a beta of 1.19. Simulations Plus has a 1 year low of $11.09 and a 1 year high of $36.45.

Analyst Ratings Changes

Several research firms have issued reports on SLP. BTIG Research downgraded Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. TD Cowen reiterated a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Zacks Research downgraded Simulations Plus from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Citigroup reiterated a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Simulations Plus presently has an average rating of “Hold” and an average price target of $25.00.

Hedge Funds Weigh In On Simulations Plus

A number of large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Simulations Plus by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock valued at $233,000 after purchasing an additional 390 shares during the period. Deutsche Bank AG grew its stake in shares of Simulations Plus by 5.9% in the 4th quarter. Deutsche Bank AG now owns 15,825 shares of the technology company’s stock valued at $288,000 after buying an additional 875 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Simulations Plus by 5.7% in the 2nd quarter. Prudential Financial Inc. now owns 17,213 shares of the technology company’s stock valued at $300,000 after buying an additional 930 shares in the last quarter. Invesco Ltd. grew its stake in shares of Simulations Plus by 3.8% in the 2nd quarter. Invesco Ltd. now owns 36,452 shares of the technology company’s stock valued at $636,000 after buying an additional 1,323 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Simulations Plus in the 2nd quarter valued at approximately $25,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.